HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation

This study is a Phase II clinical trial that plans to enroll 40 patients with borderline resectable pancreatic cancer harboring a KRAS G12D mutation, aiming to evaluate the efficacy of HRS-4642 in combination with Nimotuzumab and AG in borderline resectable pancreatic cancer. The study process includes a screening period (from the signing of the informed consent form until the first dose), a treatment period (from the first dose to the discontinuation of study treatment), and a follow-up period (safety follow-up and survival follow-up after the discontinuation of study treatment).

NCT Number	NCT07240766
Lead Sponsor	Zhejiang University
Conditions	Borderline Resectable Pancreatic Adenocarcinoma
Enrollment	40 participants
Start Date	2026-02-15
Primary Completion	2027-05-15 (estimated)
Study Completion	2028-11-15 (estimated)
Updated on ClinicalTrials.gov	2026-02-13